{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T23:31:41Z","timestamp":1724110301495},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T00:00:00Z","timestamp":1382486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00059-013-3986-9","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T09:29:37Z","timestamp":1382347777000},"page":"812-820","source":"Crossref","is-referenced-by-count":4,"title":["Akute und chronische Herzinsuffizienz im Spiegel der neuen ESC-Leitlinie"],"prefix":"10.1007","volume":"38","author":[{"given":"J.","family":"P\u00f6ss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Link","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,23]]},"reference":[{"key":"3986_CR1","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787\u20131847","journal-title":"Eur Heart J"},{"key":"3986_CR2","unstructured":"P\u00f6ss J, Ewen S, Link A et al (2013) Acute and chronic heart failure \u2013 innovations of the new ESC guidelines and their underlying clinical trials. Dtsch Med Wochenschr 138(25\u201326):1360\u20131364"},{"key":"3986_CR3","unstructured":"B\u00f6hm M (2013) CardioUpDate, Handbuch Kardiologie. Springer, Berlin Heidelberg New York"},{"key":"3986_CR4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"o","year":"1987","unstructured":"o A (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316(23):1429\u20131435","journal-title":"N Engl J Med"},{"key":"3986_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"o","year":"1991","unstructured":"o A (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325(5):293\u2013302","journal-title":"N Engl J Med"},{"key":"3986_CR6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"o","year":"1999","unstructured":"o A (1999) Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353(9169):2001\u20132007","journal-title":"Lancet"},{"key":"3986_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"o","year":"1999","unstructured":"o A (1999)The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353(9146):9\u201313","journal-title":"Lancet"},{"key":"3986_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215\u2013225","journal-title":"Eur Heart J"},{"key":"3986_CR9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386):772\u2013776","journal-title":"Lancet"},{"key":"3986_CR10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9386):767\u2013771","journal-title":"Lancet"},{"key":"3986_CR11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717","journal-title":"N Engl J Med"},{"key":"3986_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321","journal-title":"N Engl J Med"},{"key":"3986_CR13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","volume":"59","author":"Swedberg","year":"2012","unstructured":"Swedberg K, Zannad F, McMurray JJ et al (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 59(18):1598\u20131603","journal-title":"J Am Coll Cardiol"},{"key":"3986_CR14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","volume":"125","author":"Chatterjee","year":"2012","unstructured":"Chatterjee S, Moeller C, Shah N et al (2012) Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 125(8):817\u2013825","journal-title":"Am J Med"},{"key":"3986_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-010-0207-x","volume":"100","author":"Reil","year":"2011","unstructured":"Reil JC, Custodis F, Swedberg K et al (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100(1):11\u201319","journal-title":"Clin Res Cardiol"},{"key":"3986_CR16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"B\u00f6hm","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886\u2013894","journal-title":"Lancet"},{"key":"3986_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00392-012-0489-2","volume":"102","author":"Franke","year":"2013","unstructured":"Franke J, Wolter JS, Meme L et al (2013) Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol 102(1):23\u201331","journal-title":"Clin Res Cardiol"},{"key":"3986_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurjhf\/hfp154","volume":"12","author":"Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et al (2010) Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 12(1):75\u201381","journal-title":"Eur J Heart Fail"},{"key":"3986_CR19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875\u2013885","journal-title":"Lancet"},{"key":"3986_CR20","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","volume":"59","author":"Swedberg","year":"2012","unstructured":"Swedberg K, Komajda M, B\u00f6hm M et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 59(22):1938\u20131945","journal-title":"J Am Coll Cardiol"},{"key":"3986_CR21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/eurjhf\/hfs127","volume":"15","author":"Komajda","year":"2013","unstructured":"Komajda M, B\u00f6hm M, Borer J et al (2013) Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine\u2019s effects in patients with chronic heart failure. Eur J Heart Fail 15(1):79\u201384","journal-title":"Eur J Heart Fail"},{"key":"3986_CR22","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"Tardif","year":"2011","unstructured":"Tardif JC, O\u2019Meara E, Komajda M et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32(20):2507\u20132515","journal-title":"Eur Heart J"},{"key":"3986_CR23","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","volume":"32","author":"Ekman","year":"2011","unstructured":"Ekman I, Chassany O, Komajda M et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32(19):2395\u20132404","journal-title":"Eur Heart J"},{"key":"3986_CR24","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/eurheartj\/ehs259","volume":"33","author":"Borer","year":"2012","unstructured":"Borer JS, B\u00f6hm M, Ford I et al (2012) Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 33(22):2813\u20132820","journal-title":"Eur Heart J"},{"key":"3986_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102","author":"B\u00f6hm","year":"2013","unstructured":"B\u00f6hm M, Borer J, Ford I et al (2013) Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 102(1):11\u201322","journal-title":"Clin Res Cardiol"},{"key":"3986_CR26","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/eurjhf\/hfq192","volume":"12","author":"Dickstein","year":"2010","unstructured":"Dickstein K, Vardas PE, Auricchio A et al (2010) 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 12(11):1143\u20131153","journal-title":"Eur J Heart Fail"},{"key":"3986_CR27","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","volume":"363","author":"Tang","year":"2010","unstructured":"Tang AS, Wells GA, Talajic M et al (2010) Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363(25):2385\u20132395","journal-title":"N Engl J Med"},{"key":"3986_CR28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/CIRCHEARTFAILURE.112.968867","volume":"5","author":"Healey","year":"2012","unstructured":"Healey JS, Hohnloser SH, Exner DV et al (2012) Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 5(5):566\u2013570","journal-title":"Circ Heart Fail"},{"key":"3986_CR29","unstructured":"Hasenfu\u00df G, Anker SD, Bauersachs J et al (2012) Pocket-Leitlinien: Herzinsuffizienz Update 2012. Deutsche Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung e.V., D\u00fcsseldorf"},{"key":"3986_CR30","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M et al (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297(17):1883\u20131891","journal-title":"JAMA"},{"key":"3986_CR31","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/CCM.0b013e31820a91ed","volume":"39","author":"B\u00f6hm","year":"2011","unstructured":"B\u00f6hm M, Link A, Cai D et al (2011) Beneficial association of beta-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med 39(5):940\u2013944","journal-title":"Crit Care Med"},{"key":"3986_CR32","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","volume":"33","author":"Metra","year":"2012","unstructured":"Metra M, Cotter G, Gheorghiade M et al (2012) The role of the kidney in heart failure. Eur Heart J 33(17):2135\u20132142","journal-title":"Eur Heart J"},{"key":"3986_CR33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","volume":"363","author":"Massie","year":"2010","unstructured":"Massie BM, O\u2019Connor CM, Metra M et al (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363(15):1419\u20131428","journal-title":"N Engl J Med"},{"key":"3986_CR34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","volume":"41","author":"Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41(6):997\u20131003","journal-title":"J Am Coll Cardiol"},{"key":"3986_CR35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","volume":"149","author":"Adams","year":"2005","unstructured":"Adams KF Jr, Fonarow GC, Emerman CL et al (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209\u2013216","journal-title":"Am Heart J"},{"key":"3986_CR36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","volume":"365","author":"O","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365(1):32\u201343","journal-title":"N Engl J Med"},{"key":"3986_CR37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr et al (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12):1319\u20131331","journal-title":"JAMA"},{"key":"3986_CR38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ et al (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325(21):1468\u20131475","journal-title":"N Engl J Med"},{"key":"3986_CR39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","volume":"138","author":"O","year":"1999","unstructured":"O\u2019Connor CM, Gattis WA, Uretsky BF et al (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138(1 Pt 1):78\u201386","journal-title":"Am Heart J"},{"key":"3986_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00392-013-0573-2","volume":"102","author":"Lavall","year":"2013","unstructured":"Lavall D, Reil JC, B\u00f6hm M (2013) Intracardiac fistula due to prosthetic aortic valve abscess causing acute heart failure. Clin Res Cardiol 102(7):543\u2013545","journal-title":"Clin Res Cardiol"},{"key":"3986_CR41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00392-011-0297-0","volume":"100","author":"Moller","year":"2011","unstructured":"Moller M, Volz J, Paliege R et al (2011) Cardiogenic shock due to dynamic left ventricular outflow tract obstruction in acute myocardial infarction. Clin Res Cardiol 100(7):621\u2013625","journal-title":"Clin Res Cardiol"},{"key":"3986_CR42","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1152\/ajpregu.00156.2011","volume":"301","author":"Conrad","year":"2011","unstructured":"Conrad KP (2011) Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 301(2):R267\u2013R275","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3986_CR43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","volume":"381","author":"Teerlink","year":"2013","unstructured":"Teerlink JR, Cotter G, Davison BA et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381(9860):29\u201339","journal-title":"Lancet"},{"key":"3986_CR44","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","volume":"373","author":"Teerlink","year":"2009","unstructured":"Teerlink JR, Metra M, Felker GM et al (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373(9673):1429\u20131439","journal-title":"Lancet"},{"key":"3986_CR45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA et al (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797\u2013805","journal-title":"N Engl J Med"},{"key":"3986_CR46","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","volume":"367","author":"Bart","year":"2012","unstructured":"Bart BA, Goldsmith SR, Lee KL et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367(24):2296\u20132304","journal-title":"N Engl J Med"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-3986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-013-3986-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-013-3986-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:56:42Z","timestamp":1558540602000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-013-3986-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,23]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3986"],"URL":"https:\/\/doi.org\/10.1007\/s00059-013-3986-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,23]]}}}